nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—CYP2C19—prostate cancer	0.223	1	CbGaD
Tapentadol—UGT2B7—Epirubicin—prostate cancer	0.0611	0.148	CbGbCtD
Tapentadol—CYP2C19—Bicalutamide—prostate cancer	0.045	0.109	CbGbCtD
Tapentadol—CYP2C19—Nilutamide—prostate cancer	0.045	0.109	CbGbCtD
Tapentadol—CYP2C9—Nilutamide—prostate cancer	0.0374	0.0908	CbGbCtD
Tapentadol—CYP2C9—Bicalutamide—prostate cancer	0.0374	0.0908	CbGbCtD
Tapentadol—CYP2C19—Flutamide—prostate cancer	0.0373	0.0905	CbGbCtD
Tapentadol—CYP2D6—Bicalutamide—prostate cancer	0.0342	0.083	CbGbCtD
Tapentadol—CYP2D6—Abiraterone—prostate cancer	0.0284	0.0688	CbGbCtD
Tapentadol—CYP2C9—Estrone—prostate cancer	0.0224	0.0544	CbGbCtD
Tapentadol—CYP2C9—Capecitabine—prostate cancer	0.017	0.0412	CbGbCtD
Tapentadol—CYP2C19—Estradiol—prostate cancer	0.0155	0.0376	CbGbCtD
Tapentadol—CYP2C19—Prednisone—prostate cancer	0.0133	0.0323	CbGbCtD
Tapentadol—CYP2C9—Estradiol—prostate cancer	0.0129	0.0312	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—prostate cancer	0.00524	0.0127	CbGbCtD
Tapentadol—Edrophonium—ACHE—prostate cancer	0.00193	0.457	CrCbGaD
Tapentadol—Rivastigmine—ACHE—prostate cancer	0.00179	0.425	CrCbGaD
Tapentadol—CYP2C19—urine—prostate cancer	0.00178	0.15	CbGeAlD
Tapentadol—UGT2B7—prostate gland—prostate cancer	0.00139	0.117	CbGeAlD
Tapentadol—CYP2C9—urine—prostate cancer	0.00138	0.116	CbGeAlD
Tapentadol—OPRK1—prostate gland—prostate cancer	0.00131	0.11	CbGeAlD
Tapentadol—UGT1A9—renal system—prostate cancer	0.00117	0.0987	CbGeAlD
Tapentadol—CYP2D6—urine—prostate cancer	0.00104	0.0872	CbGeAlD
Tapentadol—UGT2B7—renal system—prostate cancer	0.000946	0.0795	CbGeAlD
Tapentadol—OPRD1—renal system—prostate cancer	0.000928	0.078	CbGeAlD
Tapentadol—UGT2B7—testis—prostate cancer	0.000611	0.0514	CbGeAlD
Tapentadol—Rivastigmine—CYP3A4—prostate cancer	0.000497	0.118	CrCbGaD
Tapentadol—OPRM1—testis—prostate cancer	0.000409	0.0344	CbGeAlD
Tapentadol—SLC6A2—testis—prostate cancer	0.000299	0.0252	CbGeAlD
Tapentadol—CYP2D6—renal system—prostate cancer	0.000254	0.0213	CbGeAlD
Tapentadol—SLC6A2—lymph node—prostate cancer	0.000217	0.0182	CbGeAlD
Tapentadol—CYP2D6—testis—prostate cancer	0.000164	0.0138	CbGeAlD
Tapentadol—Upper respiratory tract infection—Doxorubicin—prostate cancer	8.16e-05	0.000399	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—prostate cancer	8.11e-05	0.000396	CcSEcCtD
Tapentadol—Arthralgia—Capecitabine—prostate cancer	8.08e-05	0.000395	CcSEcCtD
Tapentadol—Confusional state—Docetaxel—prostate cancer	8.06e-05	0.000394	CcSEcCtD
Tapentadol—Anxiety—Capecitabine—prostate cancer	8.05e-05	0.000394	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.02e-05	0.000392	CcSEcCtD
Tapentadol—Anaphylactic shock—Docetaxel—prostate cancer	8e-05	0.000391	CcSEcCtD
Tapentadol—Oedema—Docetaxel—prostate cancer	8e-05	0.000391	CcSEcCtD
Tapentadol—Vision blurred—Prednisone—prostate cancer	7.96e-05	0.000389	CcSEcCtD
Tapentadol—Infection—Docetaxel—prostate cancer	7.94e-05	0.000388	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—prostate cancer	7.94e-05	0.000388	CcSEcCtD
Tapentadol—Feeling abnormal—Etoposide—prostate cancer	7.93e-05	0.000388	CcSEcCtD
Tapentadol—Diarrhoea—Mitoxantrone—prostate cancer	7.91e-05	0.000387	CcSEcCtD
Tapentadol—Dry mouth—Capecitabine—prostate cancer	7.9e-05	0.000386	CcSEcCtD
Tapentadol—Vomiting—Estradiol—prostate cancer	7.89e-05	0.000386	CcSEcCtD
Tapentadol—Shock—Docetaxel—prostate cancer	7.87e-05	0.000385	CcSEcCtD
Tapentadol—Nervous system disorder—Docetaxel—prostate cancer	7.84e-05	0.000383	CcSEcCtD
Tapentadol—Rash—Estradiol—prostate cancer	7.83e-05	0.000383	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—prostate cancer	7.82e-05	0.000383	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—prostate cancer	7.82e-05	0.000383	CcSEcCtD
Tapentadol—Dermatitis—Estradiol—prostate cancer	7.82e-05	0.000382	CcSEcCtD
Tapentadol—Confusional state—Capecitabine—prostate cancer	7.81e-05	0.000382	CcSEcCtD
Tapentadol—Tachycardia—Docetaxel—prostate cancer	7.8e-05	0.000382	CcSEcCtD
Tapentadol—Headache—Estradiol—prostate cancer	7.78e-05	0.00038	CcSEcCtD
Tapentadol—Skin disorder—Docetaxel—prostate cancer	7.77e-05	0.00038	CcSEcCtD
Tapentadol—Agitation—Prednisone—prostate cancer	7.76e-05	0.00038	CcSEcCtD
Tapentadol—Oedema—Capecitabine—prostate cancer	7.74e-05	0.000379	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—prostate cancer	7.73e-05	0.000378	CcSEcCtD
Tapentadol—Angioedema—Prednisone—prostate cancer	7.72e-05	0.000378	CcSEcCtD
Tapentadol—Infection—Capecitabine—prostate cancer	7.69e-05	0.000376	CcSEcCtD
Tapentadol—Urticaria—Etoposide—prostate cancer	7.64e-05	0.000374	CcSEcCtD
Tapentadol—Shock—Capecitabine—prostate cancer	7.62e-05	0.000372	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—prostate cancer	7.61e-05	0.000372	CcSEcCtD
Tapentadol—Nervous system disorder—Capecitabine—prostate cancer	7.59e-05	0.000371	CcSEcCtD
Tapentadol—Vertigo—Prednisone—prostate cancer	7.59e-05	0.000371	CcSEcCtD
Tapentadol—Syncope—Prednisone—prostate cancer	7.58e-05	0.000371	CcSEcCtD
Tapentadol—Tachycardia—Capecitabine—prostate cancer	7.56e-05	0.00037	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—prostate cancer	7.55e-05	0.000369	CcSEcCtD
Tapentadol—Skin disorder—Capecitabine—prostate cancer	7.52e-05	0.000368	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—prostate cancer	7.5e-05	0.000367	CcSEcCtD
Tapentadol—Hyperhidrosis—Capecitabine—prostate cancer	7.48e-05	0.000366	CcSEcCtD
Tapentadol—Hypotension—Docetaxel—prostate cancer	7.47e-05	0.000365	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—prostate cancer	7.46e-05	0.000365	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—prostate cancer	7.44e-05	0.000364	CcSEcCtD
Tapentadol—Loss of consciousness—Prednisone—prostate cancer	7.43e-05	0.000363	CcSEcCtD
Tapentadol—Nausea—Estradiol—prostate cancer	7.37e-05	0.000361	CcSEcCtD
Tapentadol—Vomiting—Mitoxantrone—prostate cancer	7.35e-05	0.00036	CcSEcCtD
Tapentadol—Convulsion—Prednisone—prostate cancer	7.32e-05	0.000358	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—prostate cancer	7.32e-05	0.000358	CcSEcCtD
Tapentadol—Rash—Mitoxantrone—prostate cancer	7.29e-05	0.000357	CcSEcCtD
Tapentadol—Dermatitis—Mitoxantrone—prostate cancer	7.29e-05	0.000356	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.28e-05	0.000356	CcSEcCtD
Tapentadol—Headache—Mitoxantrone—prostate cancer	7.25e-05	0.000354	CcSEcCtD
Tapentadol—Hypotension—Capecitabine—prostate cancer	7.23e-05	0.000354	CcSEcCtD
Tapentadol—Insomnia—Docetaxel—prostate cancer	7.23e-05	0.000354	CcSEcCtD
Tapentadol—Arthralgia—Prednisone—prostate cancer	7.19e-05	0.000352	CcSEcCtD
Tapentadol—Paraesthesia—Docetaxel—prostate cancer	7.18e-05	0.000351	CcSEcCtD
Tapentadol—Anxiety—Prednisone—prostate cancer	7.17e-05	0.000351	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—prostate cancer	7.15e-05	0.00035	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.14e-05	0.000349	CcSEcCtD
Tapentadol—Dyspnoea—Docetaxel—prostate cancer	7.13e-05	0.000349	CcSEcCtD
Tapentadol—Somnolence—Docetaxel—prostate cancer	7.11e-05	0.000348	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—prostate cancer	7.09e-05	0.000347	CcSEcCtD
Tapentadol—Hypersensitivity—Etoposide—prostate cancer	7.09e-05	0.000347	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.05e-05	0.000345	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—prostate cancer	7.05e-05	0.000345	CcSEcCtD
Tapentadol—Dyspepsia—Docetaxel—prostate cancer	7.04e-05	0.000344	CcSEcCtD
Tapentadol—Insomnia—Capecitabine—prostate cancer	7e-05	0.000342	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—prostate cancer	6.99e-05	0.000342	CcSEcCtD
Tapentadol—Paraesthesia—Capecitabine—prostate cancer	6.95e-05	0.00034	CcSEcCtD
Tapentadol—Decreased appetite—Docetaxel—prostate cancer	6.95e-05	0.00034	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—prostate cancer	6.94e-05	0.000339	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Docetaxel—prostate cancer	6.9e-05	0.000338	CcSEcCtD
Tapentadol—Asthenia—Etoposide—prostate cancer	6.9e-05	0.000338	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—prostate cancer	6.9e-05	0.000338	CcSEcCtD
Tapentadol—Dyspnoea—Capecitabine—prostate cancer	6.9e-05	0.000338	CcSEcCtD
Tapentadol—Anaphylactic shock—Prednisone—prostate cancer	6.9e-05	0.000337	CcSEcCtD
Tapentadol—Oedema—Prednisone—prostate cancer	6.9e-05	0.000337	CcSEcCtD
Tapentadol—Fatigue—Docetaxel—prostate cancer	6.89e-05	0.000337	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—prostate cancer	6.89e-05	0.000337	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—prostate cancer	6.89e-05	0.000337	CcSEcCtD
Tapentadol—Nausea—Mitoxantrone—prostate cancer	6.87e-05	0.000336	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—prostate cancer	6.86e-05	0.000335	CcSEcCtD
Tapentadol—Infection—Prednisone—prostate cancer	6.85e-05	0.000335	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—prostate cancer	6.84e-05	0.000335	CcSEcCtD
Tapentadol—Constipation—Docetaxel—prostate cancer	6.84e-05	0.000334	CcSEcCtD
Tapentadol—Dyspepsia—Capecitabine—prostate cancer	6.81e-05	0.000333	CcSEcCtD
Tapentadol—Chills—Epirubicin—prostate cancer	6.81e-05	0.000333	CcSEcCtD
Tapentadol—Pruritus—Etoposide—prostate cancer	6.81e-05	0.000333	CcSEcCtD
Tapentadol—Shock—Prednisone—prostate cancer	6.78e-05	0.000332	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—prostate cancer	6.77e-05	0.000331	CcSEcCtD
Tapentadol—Nervous system disorder—Prednisone—prostate cancer	6.76e-05	0.000331	CcSEcCtD
Tapentadol—Tachycardia—Prednisone—prostate cancer	6.73e-05	0.000329	CcSEcCtD
Tapentadol—Decreased appetite—Capecitabine—prostate cancer	6.73e-05	0.000329	CcSEcCtD
Tapentadol—Skin disorder—Prednisone—prostate cancer	6.7e-05	0.000328	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Capecitabine—prostate cancer	6.68e-05	0.000327	CcSEcCtD
Tapentadol—Fatigue—Capecitabine—prostate cancer	6.67e-05	0.000326	CcSEcCtD
Tapentadol—Hyperhidrosis—Prednisone—prostate cancer	6.67e-05	0.000326	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—prostate cancer	6.65e-05	0.000325	CcSEcCtD
Tapentadol—Constipation—Capecitabine—prostate cancer	6.62e-05	0.000324	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—prostate cancer	6.61e-05	0.000323	CcSEcCtD
Tapentadol—Feeling abnormal—Docetaxel—prostate cancer	6.59e-05	0.000322	CcSEcCtD
Tapentadol—Diarrhoea—Etoposide—prostate cancer	6.58e-05	0.000322	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—prostate cancer	6.56e-05	0.000321	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—prostate cancer	6.52e-05	0.000319	CcSEcCtD
Tapentadol—Tension—Epirubicin—prostate cancer	6.48e-05	0.000317	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—prostate cancer	6.42e-05	0.000314	CcSEcCtD
Tapentadol—Feeling abnormal—Capecitabine—prostate cancer	6.38e-05	0.000312	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—prostate cancer	6.37e-05	0.000312	CcSEcCtD
Tapentadol—Dizziness—Etoposide—prostate cancer	6.36e-05	0.000311	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—prostate cancer	6.34e-05	0.00031	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—prostate cancer	6.33e-05	0.00031	CcSEcCtD
Tapentadol—Chills—Doxorubicin—prostate cancer	6.3e-05	0.000308	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Prednisone—prostate cancer	6.28e-05	0.000307	CcSEcCtD
Tapentadol—Insomnia—Prednisone—prostate cancer	6.24e-05	0.000305	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—prostate cancer	6.23e-05	0.000305	CcSEcCtD
Tapentadol—Paraesthesia—Prednisone—prostate cancer	6.19e-05	0.000303	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—prostate cancer	6.15e-05	0.000301	CcSEcCtD
Tapentadol—Urticaria—Capecitabine—prostate cancer	6.15e-05	0.000301	CcSEcCtD
Tapentadol—Vomiting—Etoposide—prostate cancer	6.12e-05	0.000299	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—prostate cancer	6.11e-05	0.000299	CcSEcCtD
Tapentadol—Agitation—Epirubicin—prostate cancer	6.07e-05	0.000297	CcSEcCtD
Tapentadol—Dyspepsia—Prednisone—prostate cancer	6.07e-05	0.000297	CcSEcCtD
Tapentadol—Rash—Etoposide—prostate cancer	6.07e-05	0.000297	CcSEcCtD
Tapentadol—Dermatitis—Etoposide—prostate cancer	6.06e-05	0.000296	CcSEcCtD
Tapentadol—Headache—Etoposide—prostate cancer	6.03e-05	0.000295	CcSEcCtD
Tapentadol—Tension—Doxorubicin—prostate cancer	6e-05	0.000293	CcSEcCtD
Tapentadol—Decreased appetite—Prednisone—prostate cancer	5.99e-05	0.000293	CcSEcCtD
Tapentadol—Fatigue—Prednisone—prostate cancer	5.95e-05	0.000291	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—prostate cancer	5.94e-05	0.00029	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—prostate cancer	5.94e-05	0.00029	CcSEcCtD
Tapentadol—Syncope—Epirubicin—prostate cancer	5.93e-05	0.00029	CcSEcCtD
Tapentadol—Constipation—Prednisone—prostate cancer	5.9e-05	0.000288	CcSEcCtD
Tapentadol—Hypersensitivity—Docetaxel—prostate cancer	5.89e-05	0.000288	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—prostate cancer	5.84e-05	0.000286	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—prostate cancer	5.81e-05	0.000284	CcSEcCtD
Tapentadol—Cough—Epirubicin—prostate cancer	5.77e-05	0.000282	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—prostate cancer	5.76e-05	0.000282	CcSEcCtD
Tapentadol—Asthenia—Docetaxel—prostate cancer	5.74e-05	0.000281	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—prostate cancer	5.73e-05	0.00028	CcSEcCtD
Tapentadol—Nausea—Etoposide—prostate cancer	5.71e-05	0.000279	CcSEcCtD
Tapentadol—Hypersensitivity—Capecitabine—prostate cancer	5.7e-05	0.000279	CcSEcCtD
Tapentadol—Feeling abnormal—Prednisone—prostate cancer	5.68e-05	0.000278	CcSEcCtD
Tapentadol—Pruritus—Docetaxel—prostate cancer	5.66e-05	0.000277	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—prostate cancer	5.63e-05	0.000275	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—prostate cancer	5.62e-05	0.000275	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—prostate cancer	5.61e-05	0.000274	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.59e-05	0.000273	CcSEcCtD
Tapentadol—Asthenia—Capecitabine—prostate cancer	5.55e-05	0.000272	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—prostate cancer	5.5e-05	0.000269	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—prostate cancer	5.49e-05	0.000269	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—prostate cancer	5.48e-05	0.000268	CcSEcCtD
Tapentadol—Urticaria—Prednisone—prostate cancer	5.48e-05	0.000268	CcSEcCtD
Tapentadol—Pruritus—Capecitabine—prostate cancer	5.48e-05	0.000268	CcSEcCtD
Tapentadol—Diarrhoea—Docetaxel—prostate cancer	5.47e-05	0.000268	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—prostate cancer	5.44e-05	0.000266	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—prostate cancer	5.4e-05	0.000264	CcSEcCtD
Tapentadol—Oedema—Epirubicin—prostate cancer	5.39e-05	0.000264	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—prostate cancer	5.39e-05	0.000264	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—prostate cancer	5.37e-05	0.000263	CcSEcCtD
Tapentadol—Infection—Epirubicin—prostate cancer	5.36e-05	0.000262	CcSEcCtD
Tapentadol—Cough—Doxorubicin—prostate cancer	5.34e-05	0.000261	CcSEcCtD
Tapentadol—Shock—Epirubicin—prostate cancer	5.31e-05	0.00026	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—prostate cancer	5.3e-05	0.000259	CcSEcCtD
Tapentadol—Diarrhoea—Capecitabine—prostate cancer	5.3e-05	0.000259	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—prostate cancer	5.29e-05	0.000259	CcSEcCtD
Tapentadol—Dizziness—Docetaxel—prostate cancer	5.29e-05	0.000259	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—prostate cancer	5.26e-05	0.000257	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—prostate cancer	5.24e-05	0.000256	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—prostate cancer	5.21e-05	0.000255	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—prostate cancer	5.21e-05	0.000255	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—prostate cancer	5.19e-05	0.000254	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.17e-05	0.000253	CcSEcCtD
Tapentadol—Dizziness—Capecitabine—prostate cancer	5.12e-05	0.00025	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—prostate cancer	5.09e-05	0.000249	CcSEcCtD
Tapentadol—Vomiting—Docetaxel—prostate cancer	5.08e-05	0.000249	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisone—prostate cancer	5.08e-05	0.000248	CcSEcCtD
Tapentadol—Rash—Docetaxel—prostate cancer	5.04e-05	0.000247	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—prostate cancer	5.04e-05	0.000246	CcSEcCtD
Tapentadol—Dermatitis—Docetaxel—prostate cancer	5.04e-05	0.000246	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—prostate cancer	5.03e-05	0.000246	CcSEcCtD
Tapentadol—Headache—Docetaxel—prostate cancer	5.01e-05	0.000245	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—prostate cancer	4.99e-05	0.000244	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—prostate cancer	4.99e-05	0.000244	CcSEcCtD
Tapentadol—Infection—Doxorubicin—prostate cancer	4.96e-05	0.000242	CcSEcCtD
Tapentadol—Asthenia—Prednisone—prostate cancer	4.95e-05	0.000242	CcSEcCtD
Tapentadol—Vomiting—Capecitabine—prostate cancer	4.92e-05	0.000241	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.91e-05	0.00024	CcSEcCtD
Tapentadol—Shock—Doxorubicin—prostate cancer	4.91e-05	0.00024	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—prostate cancer	4.89e-05	0.000239	CcSEcCtD
Tapentadol—Rash—Capecitabine—prostate cancer	4.88e-05	0.000239	CcSEcCtD
Tapentadol—Pruritus—Prednisone—prostate cancer	4.88e-05	0.000239	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—prostate cancer	4.88e-05	0.000239	CcSEcCtD
Tapentadol—Dermatitis—Capecitabine—prostate cancer	4.88e-05	0.000239	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—prostate cancer	4.87e-05	0.000238	CcSEcCtD
Tapentadol—Headache—Capecitabine—prostate cancer	4.85e-05	0.000237	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—prostate cancer	4.85e-05	0.000237	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—prostate cancer	4.84e-05	0.000237	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—prostate cancer	4.82e-05	0.000236	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—prostate cancer	4.81e-05	0.000235	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—prostate cancer	4.79e-05	0.000234	CcSEcCtD
Tapentadol—Nausea—Docetaxel—prostate cancer	4.75e-05	0.000232	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—prostate cancer	4.75e-05	0.000232	CcSEcCtD
Tapentadol—Diarrhoea—Prednisone—prostate cancer	4.72e-05	0.000231	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—prostate cancer	4.69e-05	0.000229	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—prostate cancer	4.66e-05	0.000228	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—prostate cancer	4.66e-05	0.000228	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—prostate cancer	4.65e-05	0.000227	CcSEcCtD
Tapentadol—Constipation—Epirubicin—prostate cancer	4.61e-05	0.000226	CcSEcCtD
Tapentadol—Nausea—Capecitabine—prostate cancer	4.6e-05	0.000225	CcSEcCtD
Tapentadol—Dizziness—Prednisone—prostate cancer	4.56e-05	0.000223	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.55e-05	0.000222	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—prostate cancer	4.51e-05	0.000221	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—prostate cancer	4.48e-05	0.000219	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—prostate cancer	4.45e-05	0.000218	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—prostate cancer	4.44e-05	0.000217	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—prostate cancer	4.44e-05	0.000217	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—prostate cancer	4.39e-05	0.000215	CcSEcCtD
Tapentadol—Vomiting—Prednisone—prostate cancer	4.38e-05	0.000214	CcSEcCtD
Tapentadol—Rash—Prednisone—prostate cancer	4.35e-05	0.000213	CcSEcCtD
Tapentadol—Dermatitis—Prednisone—prostate cancer	4.34e-05	0.000212	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—prostate cancer	4.34e-05	0.000212	CcSEcCtD
Tapentadol—Headache—Prednisone—prostate cancer	4.32e-05	0.000211	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.31e-05	0.000211	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—prostate cancer	4.3e-05	0.00021	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—prostate cancer	4.28e-05	0.00021	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—prostate cancer	4.27e-05	0.000209	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—prostate cancer	4.11e-05	0.000201	CcSEcCtD
Tapentadol—Nausea—Prednisone—prostate cancer	4.1e-05	0.0002	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—prostate cancer	3.97e-05	0.000194	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—prostate cancer	3.96e-05	0.000194	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—prostate cancer	3.87e-05	0.000189	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—prostate cancer	3.82e-05	0.000187	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—prostate cancer	3.69e-05	0.00018	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—prostate cancer	3.68e-05	0.00018	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—prostate cancer	3.58e-05	0.000175	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—prostate cancer	3.57e-05	0.000174	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—prostate cancer	3.53e-05	0.000173	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—prostate cancer	3.43e-05	0.000168	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—prostate cancer	3.41e-05	0.000167	CcSEcCtD
Tapentadol—Rash—Epirubicin—prostate cancer	3.4e-05	0.000166	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—prostate cancer	3.4e-05	0.000166	CcSEcCtD
Tapentadol—Headache—Epirubicin—prostate cancer	3.38e-05	0.000165	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—prostate cancer	3.3e-05	0.000161	CcSEcCtD
Tapentadol—Nausea—Epirubicin—prostate cancer	3.2e-05	0.000157	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—prostate cancer	3.17e-05	0.000155	CcSEcCtD
Tapentadol—Rash—Doxorubicin—prostate cancer	3.15e-05	0.000154	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—prostate cancer	3.14e-05	0.000154	CcSEcCtD
Tapentadol—Headache—Doxorubicin—prostate cancer	3.13e-05	0.000153	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—prostate cancer	2.96e-05	0.000145	CcSEcCtD
Tapentadol—CYP2C9—Metabolism—ACHE—prostate cancer	4.69e-06	3.24e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LEP—prostate cancer	4.69e-06	3.24e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2A6—prostate cancer	4.68e-06	3.23e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CAV1—prostate cancer	4.65e-06	3.21e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CREBBP—prostate cancer	4.64e-06	3.21e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NCOA2—prostate cancer	4.64e-06	3.21e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2A6—prostate cancer	4.64e-06	3.2e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.62e-06	3.19e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JAK2—prostate cancer	4.61e-06	3.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—prostate cancer	4.59e-06	3.18e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—prostate cancer	4.58e-06	3.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—prostate cancer	4.56e-06	3.15e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CD—prostate cancer	4.55e-06	3.14e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKR1C3—prostate cancer	4.55e-06	3.14e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PRKACB—prostate cancer	4.52e-06	3.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—prostate cancer	4.52e-06	3.12e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKR1C3—prostate cancer	4.51e-06	3.12e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MDM2—prostate cancer	4.5e-06	3.11e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PRKACB—prostate cancer	4.49e-06	3.1e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP17A1—prostate cancer	4.48e-06	3.09e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—prostate cancer	4.48e-06	3.09e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP17A1—prostate cancer	4.44e-06	3.07e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—prostate cancer	4.43e-06	3.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAP2K1—prostate cancer	4.43e-06	3.06e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A5—prostate cancer	4.43e-06	3.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—prostate cancer	4.4e-06	3.04e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.38e-06	3.03e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—prostate cancer	4.38e-06	3.02e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BAD—prostate cancer	4.37e-06	3.02e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	4.36e-06	3.01e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	4.35e-06	3.01e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2E1—prostate cancer	4.32e-06	2.99e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—prostate cancer	4.31e-06	2.98e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NOS3—prostate cancer	4.3e-06	2.97e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NQO1—prostate cancer	4.27e-06	2.95e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOA2—prostate cancer	4.27e-06	2.95e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	4.23e-06	2.92e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—prostate cancer	4.23e-06	2.92e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOA2—prostate cancer	4.23e-06	2.92e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—prostate cancer	4.22e-06	2.91e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGF2—prostate cancer	4.21e-06	2.91e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TH—prostate cancer	4.21e-06	2.91e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—prostate cancer	4.2e-06	2.91e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.19e-06	2.89e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGF—prostate cancer	4.18e-06	2.89e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IRS1—prostate cancer	4.18e-06	2.89e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP3A4—prostate cancer	4.17e-06	2.88e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOS3—prostate cancer	4.16e-06	2.87e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.15e-06	2.87e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—prostate cancer	4.11e-06	2.84e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1B1—prostate cancer	4.1e-06	2.83e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A5—prostate cancer	4.07e-06	2.81e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—prostate cancer	4.06e-06	2.81e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GSK3B—prostate cancer	4.06e-06	2.81e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JAK2—prostate cancer	4.04e-06	2.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A5—prostate cancer	4.04e-06	2.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—prostate cancer	4.02e-06	2.78e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—EP300—prostate cancer	4.02e-06	2.78e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—prostate cancer	4.02e-06	2.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—INS—prostate cancer	4.01e-06	2.77e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—prostate cancer	4e-06	2.76e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2E1—prostate cancer	3.98e-06	2.75e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GGT1—prostate cancer	3.97e-06	2.74e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—prostate cancer	3.97e-06	2.74e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	3.96e-06	2.74e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MDM2—prostate cancer	3.94e-06	2.73e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2E1—prostate cancer	3.94e-06	2.72e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NQO1—prostate cancer	3.93e-06	2.72e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—prostate cancer	3.93e-06	2.72e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CREBBP—prostate cancer	3.92e-06	2.71e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—prostate cancer	3.92e-06	2.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NCOA1—prostate cancer	3.91e-06	2.7e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NQO1—prostate cancer	3.9e-06	2.69e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—prostate cancer	3.89e-06	2.69e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNB1—prostate cancer	3.88e-06	2.68e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—prostate cancer	3.87e-06	2.68e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TH—prostate cancer	3.87e-06	2.68e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—prostate cancer	3.86e-06	2.66e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP19A1—prostate cancer	3.85e-06	2.66e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TH—prostate cancer	3.84e-06	2.65e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	3.84e-06	2.65e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP3A4—prostate cancer	3.83e-06	2.65e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.82e-06	2.64e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—prostate cancer	3.8e-06	2.63e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP3A4—prostate cancer	3.8e-06	2.63e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—prostate cancer	3.79e-06	2.62e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.78e-06	2.61e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—prostate cancer	3.78e-06	2.61e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1B1—prostate cancer	3.77e-06	2.61e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	3.74e-06	2.59e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.74e-06	2.58e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	3.72e-06	2.57e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—RXRA—prostate cancer	3.72e-06	2.57e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—prostate cancer	3.69e-06	2.55e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—prostate cancer	3.69e-06	2.55e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	3.68e-06	2.55e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	3.68e-06	2.54e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GGT1—prostate cancer	3.65e-06	2.52e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—prostate cancer	3.64e-06	2.52e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GGT1—prostate cancer	3.62e-06	2.5e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.62e-06	2.5e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EP300—prostate cancer	3.61e-06	2.49e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	3.6e-06	2.49e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOA1—prostate cancer	3.6e-06	2.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—COMT—prostate cancer	3.58e-06	2.48e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—prostate cancer	3.56e-06	2.46e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOA1—prostate cancer	3.56e-06	2.46e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGF2—prostate cancer	3.56e-06	2.46e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	3.56e-06	2.46e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP19A1—prostate cancer	3.54e-06	2.45e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—prostate cancer	3.53e-06	2.44e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—prostate cancer	3.52e-06	2.44e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP19A1—prostate cancer	3.51e-06	2.43e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOS3—prostate cancer	3.51e-06	2.43e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ITPR1—prostate cancer	3.51e-06	2.42e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—prostate cancer	3.51e-06	2.42e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—prostate cancer	3.51e-06	2.42e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.45e-06	2.38e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—prostate cancer	3.43e-06	2.37e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—prostate cancer	3.43e-06	2.37e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—RXRA—prostate cancer	3.42e-06	2.36e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—prostate cancer	3.41e-06	2.36e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JAK2—prostate cancer	3.41e-06	2.36e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	3.4e-06	2.35e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—RXRA—prostate cancer	3.39e-06	2.34e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—prostate cancer	3.38e-06	2.34e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	3.35e-06	2.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—prostate cancer	3.33e-06	2.3e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MDM2—prostate cancer	3.33e-06	2.3e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	3.32e-06	2.3e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—prostate cancer	3.32e-06	2.29e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMS—prostate cancer	3.31e-06	2.29e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.3e-06	2.28e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—COMT—prostate cancer	3.29e-06	2.28e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—prostate cancer	3.29e-06	2.27e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—prostate cancer	3.28e-06	2.27e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—prostate cancer	3.28e-06	2.26e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—EP300—prostate cancer	3.27e-06	2.26e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—COMT—prostate cancer	3.27e-06	2.26e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—prostate cancer	3.25e-06	2.25e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	3.24e-06	2.24e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—prostate cancer	3.23e-06	2.24e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ITPR1—prostate cancer	3.23e-06	2.23e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—LPL—prostate cancer	3.22e-06	2.22e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ITPR1—prostate cancer	3.2e-06	2.21e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EP300—prostate cancer	3.16e-06	2.19e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.14e-06	2.17e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—prostate cancer	3.14e-06	2.17e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—prostate cancer	3.13e-06	2.17e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—prostate cancer	3.12e-06	2.15e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.11e-06	2.15e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ERCC2—prostate cancer	3.08e-06	2.13e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—prostate cancer	3.07e-06	2.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—prostate cancer	3.07e-06	2.12e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMS—prostate cancer	3.05e-06	2.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	3.04e-06	2.1e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMS—prostate cancer	3.02e-06	2.09e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—prostate cancer	3.01e-06	2.08e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	3.01e-06	2.08e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—prostate cancer	2.99e-06	2.07e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—prostate cancer	2.99e-06	2.06e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—prostate cancer	2.98e-06	2.06e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—prostate cancer	2.98e-06	2.06e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—prostate cancer	2.97e-06	2.06e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—prostate cancer	2.96e-06	2.05e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—prostate cancer	2.96e-06	2.05e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—LPL—prostate cancer	2.96e-06	2.04e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—LPL—prostate cancer	2.93e-06	2.03e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—prostate cancer	2.9e-06	2.01e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—prostate cancer	2.9e-06	2.01e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—prostate cancer	2.9e-06	2e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	2.87e-06	1.99e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.86e-06	1.97e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARA—prostate cancer	2.84e-06	1.96e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ERCC2—prostate cancer	2.83e-06	1.96e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.83e-06	1.96e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—prostate cancer	2.82e-06	1.95e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ERCC2—prostate cancer	2.81e-06	1.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	2.81e-06	1.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—prostate cancer	2.8e-06	1.94e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—prostate cancer	2.76e-06	1.9e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—prostate cancer	2.75e-06	1.9e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—prostate cancer	2.73e-06	1.89e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—prostate cancer	2.69e-06	1.86e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EP300—prostate cancer	2.67e-06	1.85e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAV1—prostate cancer	2.67e-06	1.85e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	2.67e-06	1.84e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—prostate cancer	2.66e-06	1.84e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—prostate cancer	2.64e-06	1.82e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARA—prostate cancer	2.61e-06	1.81e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—prostate cancer	2.6e-06	1.8e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARA—prostate cancer	2.59e-06	1.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—prostate cancer	2.58e-06	1.78e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.55e-06	1.76e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—prostate cancer	2.55e-06	1.76e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—prostate cancer	2.53e-06	1.75e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—prostate cancer	2.51e-06	1.73e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAV1—prostate cancer	2.46e-06	1.7e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAV1—prostate cancer	2.43e-06	1.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.43e-06	1.68e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—prostate cancer	2.43e-06	1.68e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—prostate cancer	2.42e-06	1.67e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—prostate cancer	2.36e-06	1.63e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	2.34e-06	1.62e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—prostate cancer	2.33e-06	1.61e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.33e-06	1.61e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—prostate cancer	2.32e-06	1.61e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—INS—prostate cancer	2.3e-06	1.59e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—prostate cancer	2.28e-06	1.57e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—prostate cancer	2.26e-06	1.56e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CREBBP—prostate cancer	2.26e-06	1.56e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.24e-06	1.55e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.22e-06	1.53e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—prostate cancer	2.18e-06	1.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—prostate cancer	2.15e-06	1.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.14e-06	1.48e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—INS—prostate cancer	2.12e-06	1.46e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—INS—prostate cancer	2.1e-06	1.45e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CREBBP—prostate cancer	2.07e-06	1.43e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—prostate cancer	2.07e-06	1.43e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CREBBP—prostate cancer	2.06e-06	1.42e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NOS3—prostate cancer	2.02e-06	1.4e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	1.98e-06	1.37e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—prostate cancer	1.97e-06	1.37e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.97e-06	1.36e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.95e-06	1.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—prostate cancer	1.91e-06	1.32e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—prostate cancer	1.91e-06	1.32e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.86e-06	1.29e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NOS3—prostate cancer	1.86e-06	1.28e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—prostate cancer	1.85e-06	1.28e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NOS3—prostate cancer	1.84e-06	1.27e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—prostate cancer	1.75e-06	1.21e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.71e-06	1.18e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.7e-06	1.17e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—prostate cancer	1.7e-06	1.17e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—prostate cancer	1.68e-06	1.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—prostate cancer	1.61e-06	1.12e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—prostate cancer	1.61e-06	1.11e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—EP300—prostate cancer	1.54e-06	1.06e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—prostate cancer	1.48e-06	1.02e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—prostate cancer	1.47e-06	1.02e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—EP300—prostate cancer	1.41e-06	9.76e-06	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—EP300—prostate cancer	1.4e-06	9.68e-06	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.14e-06	7.85e-06	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.05e-06	7.22e-06	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.04e-06	7.16e-06	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—prostate cancer	9.28e-07	6.42e-06	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—prostate cancer	8.54e-07	5.9e-06	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—prostate cancer	8.46e-07	5.85e-06	CbGpPWpGaD
